Gaithersburg-based molecular diagnostics company OpGen Inc. filed Tuesday to go public in hopes of raising as much as $37.4 million.
In its initial regulatory filing with the Securities and Exchange Commission, the company said it would trade on the Nasdaq under the ticker symbol OPGN. It has yet to set a price for the stock or date for the initial public offering, which New York-based Maxim Group LLC will manage.
This spring, the InvestMaryland Challenge will award four $100,000 grand prizes to innovative young companies with the potential to flourish in Maryland.
Now in its third year, this national seed and early-stage business competition, hosted by the Maryland Department of Business and Economic Development, has accepted hundreds of applications since fall 2014. Judges have now narrowed the field to just 46 companies, including the competition’s first-ever international semifinalist, Israel-based AcceleRadio. This month, they will present their business plans during face-to-face interviews with panels of three to five judges. Final reviews will take place in April.
The Johns Hopkins University Montgomery County Campus welcomes Leidos to the campus community. Leidos has located some of its employees in Building III, putting them in close proximity to the National Cancer Institute Shady Grove, located right next door. Leidos Biomedical Research and the National Cancer Institute have a contract to work together on “genetics and genomics, proteins and proteomics, advanced biomedical computing and information technology, biopharmaceutical development and manufacturing, nanotechnology characterization, and clinical trials management,” according to NCI.
Today at Henderson’s Wharf Inn in Fells Point, U.S. Senator Barbara A. Mikulski (D-Md.) announced she has decided not to run for re-election. Senator Mikulski, who will complete her 5th term in office in January, 2017, says she wants to focus for the next two years on working for her constituents and for the nation.
“Because every day, I want to wake up thinking about you — the little guys and gals, the watermen, automobile workers, researchers, small business owners and families,” Senator Mikulski said. “I want to give you 120 percent of my time with all of my energy focused on you and your futures. Because it’s always been about you, never about me. That’s what it takes to be a good senator by my expectations and by my standards.”
Cambridge, Massachusetts-based Mersana Therapeutics Inc, a provider of Fleximer antibody-drug conjugate technology, has secured $35 million in Series B-1 financing. New Enterprise Associates led the round with participation from Rock Springs Capital Management, Elliott Sigal, former head of R&D at Bristol-Myers Squibb, Pfizer Venture Investments and Fidelity Biosciences. Also, Mersana has appointed Anna Protopapas as president and CEO. And, Protopapas and Dr. Elaine V. Jones, executive director of Pfizer Venture Investments, have been added to Mersana’s board of directors.
Sen. Barbara A. Mikulski, the Maryland Democrat who is the longest-serving woman in congressional history, will depart Capitol Hill the way she arrived — with a sharp tongue, an unabashed liberalism and a mission to make the Senate a place where women belong.
Mikulski surprised many colleagues Monday with her announcement that she will leave the Senate next year after five terms. In good health at 78, the senator said she wants to shift her focus: “Do I spend my time raising money? Or do I spend my time raising hell?”
On Feb. 19, the U.S. Food and Drug Administration took a huge step towards patient-centric medicine when it approved the marketing of genetics testing company 23andMe’s carrier test for Bloom Syndrome. This was a startling — and good — development because it affirmed the rights of consumers to drive their own health-care decisions and procedures. But it also means that it has become urgent to develop policies to regulate the rights of companies to resell data derived from the contents of our DNA and from our medical records.
There’s been a flurry of news related to telemedicine this week, with several notable developments in Mississippi and Silicon Valley.
One of the more interesting aspects of telemedicine is that much of the innovation and focus of late has come from startups and vendors, while health systems have shown a bit of reluctance to deploy it on their own.
U.S. Small Business Administration leader Maria Contreras-Sweet drew parallels Friday between Baltimore and the rust-belt city of Detroit — but she actually meant it in a positive way.
Contreras-Sweet, the SBA’s administrator, was in Baltimore and took questions about the administration’s work in the city and its overall direction. Baltimore has many highly skilled workers who can pivot to new startup businesses, much like Detroit has automobile-industry employees who can put their expertise to work elsewhere, she said.
As the landscape of the biopharmaceutical industry expands into growing regions, an exciting transformation is beginning to transfer commercialization “recipes” to emerging markets. All eyes are on small, specialty, and midsize players emerging at the forefront of innovation in the mature regions of Europe and the United States.
At the global level, the BRICK countries of Brazil, Russia, India, China, and Korea are aggressively investing in R&D, facilities, and scientist training, and vying for bigger roles not only as markets for medicines, but also as rich breeding grounds for R&D and manufacturing.
